Dr. Fabricio Tello is a preeminent authority in pharmaceutical life sciences R&D and clinical development, contributing over three decades of invaluable experience and expertise to ESTERN Medical CRO Life Sciences.

As a highly accomplished and dynamic physician, Dr. Tello boasts an impressive track record of success within the life sciences and clinical trials pharmaceutical industry. His seasoned professionalism is evident in his extensive history of spearheading the implementation and advancement of pharmacovigilance, techno-surveillance, and life science training programs for globally recognized pharmaceutical companies.

In his previous diverse roles as Medical Director, Dr. Tello played a pivotal role in directing the implementation and development of pharmacovigilance, techno-surveillance, and life science training initiatives within the pharmaceutical industry. Serving as a medical scientific liaison and regional medical advisor, he demonstrated proficiency in guiding health professionals through clinical studies and adeptly managing security health crises arising from the use of pharmaceutical products.

Dr. Tello is distinguished by his ability to influence and persuade, coupled with meticulous attention to detail that ensures results meet the highest standards of quality and excellence. His strategic insight positions him as a key asset in driving success and innovation in the pharmaceutical life sciences sector.

His extensive professional journey includes serving as a medical scientific liaison for Novo Nordisk in Latin America, specializing in diabetes and obesity arena with key vanguard molecules such as insulin Degludec, and the incretins Liraglutide and Semaglutide. Dr. Tello also held the position of Head of Pharmacovigilance in Latin America for Bayer Pharmaceuticals, providing pharmaceutical pharmacovigilance drug safety for major R&D pipeline products. Furthermore, he served as the Medical Director for Radio Pharmaceutical Management in molecular imaging within the MRI and CT department for Bayer Pharmaceuticals, working with novel molecules for diverse clinical indications such as rivaroxaban, Eylia, Betaferon, Gadovist, Ultravist, Riociguat, Regorafenib, Kogenate, and Sorafenib.

Dr. Tello earned his Medical Doctor degree from Antioquia University in Medellín, Colombia, and pursued further specialization in Health Administration at Pontificia Universidad Javeriana – Bogotá, Colombia.

Additionally, Dr. Tello holds a degree in Molecular Biology, Physiology, and Biochemistry of Microorganisms, and Bacterial Molecular Genetics from the National University. His robust educational background, coupled with his wealth of practical experience, establishes Dr. Tello as a distinguished professional in the field of pharmaceutical life sciences and clinical development.